GENEART Synthesizes Genes for Swine Flu Vaccine in Record Speed

- First constructs of H1N1 strain (swine flu) were delivered on
Friday, May 1, 2009 to one of the top 10 pharma companies
- GENEART emergency scenario enables production in 3-5 calendar days
- 10 more H1N1 genes from subsequently placed orders completed early
this week, among others for the Robert Koch Institute
- Gene synthesis offers fastest and safest access to vaccines without
need for highly pathogenic patient isolates

Regensburg, May 5, 2009 - GENEART AG, world market leader for gene
synthesis and specialist in Synthetic Biology, produced genes for the
development of a vaccine against the so called 'swine flu' for one of
the pharma top 10 customers in record time. These genes were
finalized within 3-5 calendar days, and delivered to the customer
already on May 1, 2009. One of the genes was over 1,800 base pairs in
length. In addition, 10 constructs, some ordered mid last week by the
Robert Koch Institute (RKI - the central federal institution
responsible for disease control and prevention of the German
government) were completed early this week.

The produced genes are mainly variations of the viral coat proteins
of the swine flu strain called H1N1. They were ordered on the basis
of H1N1-virus sequence data published by the World Health
Organization (WHO), and synthesized with GENEART's GeneAssembler®
synthesis platform in record speed.

"In case of a pandemic threat, gene synthesis offers the fastest,
safest and most efficient access to vaccines, because there is no
need for highly pathogenic patient isolates. GENEART has developed an
emergency plan for such scenarios where we work 24/7 to deliver in
the shortest possible time. Gene synthesis has once more proven its
outstanding importance for the development of vaccines and
pharmaceuticals", says Prof. Dr. Ralf Wagner, CEO and CSO of GENEART
AG.

For further inquiries, please contact:

Dr. Karoline Stürmer
GENEART AG
Josef-Engert-Str. 11
93053 Regensburg
Germany
Phone: +49-(0)941-942 76-417
Fax: +49-(0)941-942 76-711
ir@geneart.com
www.geneart.com

Frank Ostermair
Better Orange IR & HV AG
Haidelweg 48
81241 Munich
Germany
Phone: +49-(0)89-8896906-10
Fax: +49-(0)89-8896906-66
info@better-orange.de
www.better-orange.de

Legal Information
This document may contain estimates, prognoses and opinions about
company plans and objectives, products or services, future results,
opinions about these results or opinions leading up to these results.
All these projections into the future are subject to risk,
uncertainty and unforeseeable change outside the control of the
GENEART Group. Many factors may lead to actual results, which
considerably deviate from the given projections for these results.

About GENEART AG:
In 2000, GENEART entered the gene synthesis market and has since
become the global market leader. Today, the company is one of the
leading specialists in the Synthetic Biology field. Experts at
GENEART provide key technologies for the development and production
of new therapeutics and vaccines. Customers also take advantage of
GENEART services to customize enzyme attributes, such as the
attributes of enzymes used as detergent additives, and to construct
bacteria, which produce complex biopolymers or break down polymers,
such as synthetics, petroleum components, etc. Our production and
service spectrum spans a wide range, from the production of synthetic
genes according to DIN EN ISO 9001:2000, to the creation of gene
libraries in the combinatorial biology, to the development and
production of DNA-based biologically active substances. GENEART AG in
Regensburg (Germany) and the subsidiaries GENEART Inc. in Toronto
(Canada) and GENEART Inc. in San Francisco (USA) employ more than 190
people. GENEART is listed on the German Stock Exchange.

This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.